Filing Analysis
📝 Material Agreement
Filed May 14, 2026
🟡 MEDIUM
CEL-SCI Corporation has entered into a strategic partnership and revenue-sharing agreement with Amarox for the commercialization of Multikine in Saudi Arabia. The agreement covers regulatory affairs and marketing, with potential expansion into other Gulf Cooperation Council (GCC) countries.
📋 Key Facts
- Agreement signed on May 11, 2026, with partner Amarox.
- The partnership focuses on Multikine (Leukocyte Interleukin, Injection) for the treatment of head and neck cancer.
- The primary territory is Saudi Arabia, with an optional extension for Bahrain, Kuwait, Oman, Qatar, and the United Arab Emirates.
- The deal includes distribution and revenue-sharing components for potential commercialization.
- Amarox will handle regulatory affairs and marketing in the specified regions.
💸 Securities Offering
Filed May 13, 2026
🟡 MEDIUM
CEL-SCI Corporation entered into a placement agency agreement with ThinkEquity LLC to issue 6,000,000 shares of common stock at $1.20 per share. The offering, which closed on May 13, 2026, raised gross proceeds of $7.2 million to fund the development of the company's Multikine product and for general corporate purposes.
🚩 Red Flags
- Significant dilution for existing shareholders with the issuance of 6 million new shares.
- Relatively short lock-up periods of 30 days for the company and 45 days for insiders.
📋 Key Facts
- Issuance of 6,000,000 shares of common stock at a price of $1.20 per share.
- Gross proceeds of $7,200,000 before fees and expenses.
- Placement agent ThinkEquity LLC received a 7.0% cash fee and up to $150,000 in expense reimbursements.
- Company agreed to a 30-day lock-up period; directors and officers agreed to a 45-day lock-up period.
- Net proceeds intended for the continued development of Multikine and working capital.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.